The earnings call for Edwards Lifesciences was largely positive, with the company reporting strong double-digit sales growth and raising its full-year guidance. The Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments showed significant growth, and the company saw strong international performance. However, there were some concerns about decreased gross profit margins and the anticipated negative impact on earnings per share from the JenaValve acquisition.

Company Guidance -

Q3 2025

During the Edwards Lifesciences Second Quarter 2025 Results Conference Call, the company provided updated guidance based on their strong performance. Edwards reported total sales of $1.53 billion for Q2, reflecting a 10.6% growth, driven by their structural heart therapies portfolio. The company raised its full-year 2025 sales growth guidance to 9% to 10% and adjusted EPS guidance to the high end of $2.40 to $2.50. For the TAVR segment, global sales reached $1.1 billion, showing a 7.8% increase, with stable competitive positioning. Edwards also reported a 57% growth in their TMTT product group sales, amounting to $133 million, and a 6.8% increase in their Surgical product group sales, totaling $267 million. The company projects third-quarter sales between $1.46 billion and $1.54 billion, with adjusted EPS expected to be $0.54 to $0.60. For the entire fiscal year 2025, the company forecasts total sales between $5.9 billion and $6.1 billion.

Double-Digit Sales Growth

Edwards Lifesciences reported double-digit sales growth in the second quarter, with total sales of $1.53 billion, representing a 10.6% increase which was better than expected.

Raised Full Year Guidance

Based on strong first-half performance, Edwards Lifesciences raised its full year 2025 sales growth guidance to 9% to 10% and adjusted EPS guidance to the high end of the original range of $2.40 to $2.50.

TAVR Sales Growth

The Transcatheter Aortic Valve Replacement (TAVR) segment saw global sales of $1.1 billion, increasing by 7.8% over the prior year.

Strong TMTT Growth

The Transcatheter Mitral and Tricuspid Therapies (TMTT) product group drove impressive growth with sales of $133 million, a 57% increase.

Strong International Performance

Edwards Lifesciences saw strong international sales growth, particularly in Europe and Japan, contributing to their overall performance.

Edwards Lifesciences (EW) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EW Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	0.59 / -	0.67	―	―	―
Jul 24, 2025	2025 (Q2)	0.62 / 0.67	0.7	-4.29% (-0.03)	―
Apr 23, 2025	2025 (Q1)	0.60 / 0.64	0.66	-3.03% (-0.02)	―
Feb 11, 2025	2024 (Q4)	0.55 / 0.59	0.64	-7.81% (-0.05)	―
Oct 24, 2024	2024 (Q3)	0.67 / 0.67	0.59	13.56% (+0.08)	―
Jul 24, 2024	2024 (Q2)	0.69 / 0.70	0.66	6.06% (+0.04)	―
Apr 25, 2024	2024 (Q1)	0.64 / 0.66	0.62	6.45% (+0.04)	―
Feb 06, 2024	2023 (Q4)	0.64 / 0.64	0.64	0.00% (0.00)	―
Oct 25, 2023	2023 (Q3)	0.59 / 0.59	0.61	-3.28% (-0.02)	―
Jul 26, 2023	2023 (Q2)	0.65 / 0.66	0.63	4.76% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EW Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	$75.80	$80.00	+5.54%
Apr 23, 2025	$70.46	$75.13	+6.63%
Feb 11, 2025	$70.91	$75.82	+6.92%
Oct 24, 2024	$70.35	$69.38	-1.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Edwards Lifesciences (EW) report earnings?

Edwards Lifesciences (EW) is schdueled to report earning on Oct 22, 2025, After Close (Confirmed).

What is Edwards Lifesciences (EW) earnings time?

Edwards Lifesciences (EW) earnings time is at Oct 22, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EW EPS forecast?

EW EPS forecast for the fiscal quarter 2025 (Q3) is 0.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing